Human papillomavirus type 18 E6 and E7 oncoproteins (HPV-18 E6/E7)

Human papillomavirus type 18 (HPV-18) E6 and E7 are potent viral oncoproteins essential for the initiation and maintenance of the malignant phenotype in HPV-associated cancers. The E6 protein facilitates the ubiquitination and subsequent proteasomal degradation of the host tumor suppressor protein p53, thereby inhibiting apoptosis and allowing the accumulation of DNA damage (Source: NIH, PubMed). Simultaneously, the E7 protein binds to and inactivates the retinoblastoma protein (pRb), which releases E2F transcription factors and drives the cell into the S-phase of the cell cycle, promoting uncontrolled proliferation (Source: UniProt, StatPearls). Because these proteins are constitutively expressed in HPV-transformed cells and are absent in healthy tissues, they represent ideal targets for therapeutic vaccines and gene-silencing technologies. Current clinical efforts focus on stimulating cytotoxic T-lymphocyte responses to eliminate E6/E7-expressing tumor cells, particularly in high-grade cervical intraepithelial neoplasia and advanced HPV-positive malignancies (Source: PubMed, ClinicalTrials.gov).

Other names

HPV18 E6HPV18 E7Human papillomavirus 18 early protein 6Human papillomavirus 18 early protein 7HPV-18 E6/E7

Therapeutic interventions targeting HPV-18 E6 and E7 primarily utilize immunotherapy, such as DNA vaccines or peptide vaccines, to induce a T-cell mediated immune response against cells expressing these viral proteins. Experimental approaches also include siRNA or CRISPR/Cas9 to directly silence or disrupt the E6 and E7 genes, thereby restoring the function of host tumor suppressors p53 and pRb.